Citations

Showing 10 of 108104 citations.

Dermatofibrosarcoma Protuberans Recurrence After Wide Local Excision Versus Mohs Micrographic Surgery: A Systematic Review and Meta-Analysis
Martin, Emma C. St., Vyas, Krishna S., Batbold, Sarah, Erwin, Patricia J., Brewer, Jerry D., Vyas, Krishna S. , Martin, Emma C. St., Vyas, Krishna S., Batbold, Sarah, Erwin, Patricia J., Brewer, Jerry D.

Mayo Clinic

Dermatologic Surgery | March 30, 2022 | Volume: 48 | Issue: 5 | Pages: 479-485

10.1097/dss.0000000000003411 | PMID 35353755 Get It

BACKGROUND Local recurrence (LR) rates of dermatofibrosarcoma protuberans (DFSP) treated with different surgical modalities are unknown. OBJECTIVE To evaluate the differences in LR rates of DFSP treated with wide local excision (WLE) versus Mohs micrographic surgery (MMS). MATERIALS AND METHODS Pertinent studies of DFSP treated with either WLE or MMS were identified through a search of multiple databases, including Ovid MEDLINE (1946–2018), Embase (1988–2018), Web of Science (1975–2018), and Scopus (1970–2018). Comparative 2-arm and noncomparative single-arm studies were assessed through meta-analyses. RESULTS Of the 517 studies identified, 88 met inclusion criteria (12 comparative studies; 76 single-arm studies). In the 12 comparative studies, 352 patients with DFSP underwent MMS and 777 patients with DFSP underwent WLE. The LR rate was 1.7% after MMS and 3.7% after WLE (odds ratio, 1.549; 95% CI, 0.710–3.381; p = .27). In the 76 noncomparative studies, 980 patients underwent MMS (LR rate, 1.5%; 95% CI, 0.9%–2.1%; p < .001), and 2,215 patients underwent WLE (LR rate, 9.4%; 95% CI, 7.5%–11.3%; p < .001). CONCLUSION The LR rate of DFSP in patients treated with MMS is lower than in patients treated with WLE. Because of high rates of postoperative DFSP LR, MMS should be strongly considered when available.
The Use of Acellular Hydrated Dermis as a Biologic Dressing for Post-Mohs Micrographic Surgery Wounds Extending to Bone
Mullen, Barbara L., Ahn, Ji Won, Arpey, Christopher J., Mullen, Barbara L., Ahn, Ji Won, Arpey, Christopher J.

Mayo Clinic

Dermatologic Surgery | March 30, 2022 | Volume: 48 | Issue: 6 | Pages: 682-683

10.1097/dss.0000000000003422 | PMID 35353753 Get It

Mycotic and non-mycotic coronary artery aneurysms—A review of the rarity
Kukkar, Vishal, Kapoor, Harit, Aggarwal, Amit, Kukkar, Vishal, Kapoor, Harit, Aggarwal, Amit

Mayo Clinic

Journal of Clinical Imaging Science | March 30, 2022 | Volume: 12 | Issue: No issue available | Pages: 13

10.25259/jcis_218_2021 | PMID 35414960 Get It

Sir William Osler coined the term “mycotic” to identify aneurysms secondary to an infectious cause, which may not be necessarily fungal and are caused mainly by bacteria. The literature’s reported incidence of coronary artery aneurysms (CAA) is from 1.5-5%. The right coronary artery (RCA) is mainly involved, followed by the left side coronary circulation. Mycotic aneurysms are more commonly associated with infective endocarditis. More recently, coronary artery stents, particularly drug-eluting stents, are typically causing mycotic coronary aneurysms. CT angiography (CTA) has been the forefront diagnostic modality, showing both the lumen and wall of the coronary arteries. It also aids in preoperative planning. MRI is useful in diagnosing and following children with Kawasaki’s disease. Smaller mycotic coronary aneurysms may resolve with antibiotic therapy; however, aneurysms more significant than 1-2 cm diameter needs corrective surgery. Early diagnosis and appropriate management are the critical factors in the successful treatment of infective coronary artery aneurysms.
Canagliflozin-associated severe hyponatremia: a rare and potentially adverse effect?
Dhanasekaran, Maheswaran , Narayanan, Siddharth , Mehta, Suchita, Mastoris, Ioannis

Mayo Clinic

Endocrinology, Diabetes & Metabolism Case Reports | March 30, 2022 | Volume: 2022 | Issue: No issue available | Pages: No page available

10.1530/edm-21-0035 | PMID 35352682 Get It

Summary Sodium-glucose cotransporter-2 inhibitors (SGLT2i) induce osmotic diuresis by inhibiting the proximal renal tubular reabsorption of the filtered glucose load, which in turn can occasionally lead to severe dehydration and hypotension amidst other adverse effects. We present a case of a 49-year-old man with type 2 diabetes mellitus (T2D) on canagliflozin, a SGLT2i. The patient was brought to the emergency room following a motor vehicle accident. He was confused and had an altered mental status. His blood alcohol and urine toxicology screens were negative. Initial investigations revealed that he had severe hyponatremia with euglycemic ketoacidosis. The adverse condition was reversed with close monitoring and timely management, and the patient was eventually discharged. This is the first report to suggest hyponatremia as a potentially serious adverse effect following SGLT2i therapy. Its impact on the renal tubule handling of sodium and water is not yet well characterized. While further studies are warranted to understand better the pathophysiological mechanisms associated with SGLT2i-induced adverse effects, timely dose reduction or perhaps even its temporary discontinuation may be recommended to prevent complications. Learning points Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are usually well-tolerated, but some serious adverse effects have been documented. Our case report suggests hyponatremia as a potential, rare side effect of SGLT2i and makes physicians aware of the occurrence of such life-threatening but preventable complications. Timely and close monitoring of the patient, with temporary discontinuation of this drug, may be recommended towards effective management. Studies demonstrating a comprehensive understanding of SGLT2i-related electrolyte derangements are warranted.
Neurostimulation in people with drug‐resistant epilepsy: Systematic review and meta‐analysis from the ILAE Surgical Therapies Commission
Touma, Lahoud , Dansereau, Bénédicte, Chan, Alvin Y. , Jetté, Nathalie , Braun, Kees P. J. , Jehi, Lara , Rolston, John D. , Vadera, Sumeet, Englot, Dario J. , Keezer, Mark R. , Kwon, Churl-Su , Jehi, Lara , Rolston, John D , Wong-Kisiel, Lily C. , Englot, Dario J , Keezer, Mark R , Jette, Nathalie , Friedman, Daniel, Wong‐Kisiel, Lily C.

Mayo Clinic

Epilepsia | March 30, 2022 | Volume: 63 | Issue: 6 | Pages: 1314-1329

10.1111/epi.17243 | PMID 35352349 Get It

AbstractObjectiveSummarize the current evidence on efficacy and tolerability of vagus nerve stimulation (VNS), responsive neurostimulation (RNS), and deep brain stimulation (DBS) through a systematic review and meta‐analysis.MethodsWe followed the Preferred Reporting Items of Systematic reviews and Meta‐Analyses reporting standards and searched Ovid Medline, Ovid Embase, and the Cochrane Central Register of Controlled Trials. We included published randomized controlled trials (RCTs) and their corresponding open‐label extension studies, as well as prospective case series, with ≥20 participants (excluding studies limited to children). Our primary outcome was the mean (or median, when unavailable) percentage decrease in frequency, as compared to baseline, of all epileptic seizures at last follow‐up. Secondary outcomes included the proportion of treatment responders and proportion with seizure freedom.ResultsWe identified 30 eligible studies, six of which were RCTs. At long‐term follow‐up (mean 1.3 years), five observational studies for VNS reported a pooled mean percentage decrease in seizure frequency of 34.7% (95% confidence interval [CI]: −5.1, 74.5). In the open‐label extension studies for RNS, the median seizure reduction was 53%, 66%, and 75% at 2, 5, and 9 years of follow‐up, respectively. For DBS, the median reduction was 56%, 65%, and 75% at 2, 5, and 7 years, respectively. The proportion of individuals with seizure freedom at last follow‐up increased significantly over time for DBS and RNS, whereas a positive trend was observed for VNS. Quality of life was improved in all modalities. The most common complications included hoarseness, and cough and throat pain for VNS and implant site pain, headache, and dysesthesia for DBS and RNS.SignificanceNeurostimulation modalities are an effective treatment option for drug‐resistant epilepsy, with improving outcomes over time and few major complications. Seizure‐reduction rates among the three therapies were similar during the initial blinded phase. Recent long‐term follow‐up studies are encouraging for RNS and DBS but are lacking for VNS.
Virtual Reality for Health Care Professionals During a Pandemic: A Pilot Program
Croghan, Ivana T. , Aakre, Christopher A. , Fokken, Shawn C. , Lindeen, Stephanie A. , Schroeder, Darrell R. , Ganesh, Ravindra , Ghosh, Karthik, Bauer, Brent A. , Hurt, Ryan T. , Lindeen, Stephanie A , Ganesh, Ravindra , Schroeder, Darrell , Fischer, Karen M.

Mayo Clinic

Journal of Primary Care & Community Health | March 30, 2022 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/21501319221086716 | PMID 35352605 Get It

Objective: The purpose of this pilot study was to evaluate the safety and use of a nature-based virtual reality (VR) experience among health care providers (HCP) during a pandemic. Methods: Twenty-four frontline HCP participated in this crossover pilot where the viewing order of the experiences were randomized. All participants attended in-person consent, baseline, and end-of-study visits. The intervention consisted of viewing 2 nature-based scenes (“walk in the woods” and “forest of focus”) through 3-D VR and with computer 4K graphic imagery. Randomization took place with regards to the viewing order (VR vs 4K computer video, scene 1 and 2). Outcomes measured were safety, acceptability and changes in intensity of anxiety feelings, resilience, emotional distress, cognitive function, and self-efficacy. Results: Among the 26 HCP expressing interest in the study, 24 enrolled in this study. The majority were male (58.3%), white (66.7%) and of an average age of 46.3 ± 10.5 years (standard deviation (SD)). End of the study survey showed that almost all participants (96%) would participate in the study again and recommend it to others. Twenty-three of the 24 participants also felt relaxed after seeing the imagery. With respect to anxiety (as measured by the STAI Y1), the VR “walk in the woods” had the greatest reduction from pre to post (6.4 points, SD = 5.98) followed by VR “forest of focus” (5.8 points, SD = 9.29), computer screen “forest of focus” (5.0 points, SD = 8.89), and computer screen “walk in the woods” (4.1 points, SD = 6.22). All 4 sessions had a significant decrease in score from pre to post (P-values ≤.005), but there was no significant difference in the change from pre- to post-session between the 4 groups (P-value = .5835). Conclusion: The use of the VR among HCP has promise for reducing stress among health care providers during a high stress period, such as a pandemic but much larger studies are needed.
The effect of gluten in adolescents and young adults with gastrointestinal symptoms: a blinded randomised cross‐over trial
Crawley, Cæcilie , Savino, Nadia, Halby, Cecilie, Sander, Stine Dydensborg , Andersen, Anne‐Marie Nybo , Arumugam, Manimozhiyan , Murray, Joseph A. , Christensen, Robin , Husby, Steffen , Murray, J A

Mayo Clinic

Alimentary Pharmacology & Therapeutics | March 30, 2022 | Volume: 55 | Issue: 9 | Pages: 1116-1127

10.1111/apt.16914 | PMID 35352373 Get It

AbstractBackgroundThe popularity of the gluten‐free diet and sales of gluten‐free products have increased immensely.AimsTo investigate whether gluten induces gastrointestinal symptoms, measured by self‐reported questionnaires, as well as mental health symptoms in adolescents from a population‐based cohort.MethodsThe eligible participants (n = 273) were recruited from a population‐based cohort of 1266 adolescents and had at least four different gastrointestinal symptoms. Phase one (n = 54) was a run‐in phase where the participants lived gluten‐free for 2 weeks. If they improved they continued to phase 2 (n = 33), a blinded randomised cross‐over trial. Participants were blindly randomised either to start with 7 days of gluten, eating two granola bars containing 10 g of gluten or to 7 days on placebo, eating two granola bars without gluten, followed by the reverse and separated by a 7‐day washout period. The effects of the intervention on gastrointestinal symptoms and mental health symptoms were assessed.ResultsIn total, 54/273 participants entered the run‐in phase and 35 were eligible for randomization. A total of 33 were randomised and 32 completed the trial. The median age was 20.3 (IQR 19.2–20.9) and 32/33 participants were females. Compared with a placebo, gluten did not induce gastrointestinal symptoms. The difference in the average VAS was −0.01 (95% confidence interval −2.07 to 2.05). Nor did we find a difference in the outcomes measuring mental health.ConclusionCompared with placebo, adding gluten to the diet did not induce gastrointestinal symptoms or worsened mental health in adolescents recruited from a population‐based cohort. The trial registration number is NCT04639921.
Effects of COVID-19 pandemic on mental health of children and adolescents: A systematic review of survey studies
Theberath, Monique, Bauer, David A, Chen, Weizhi , Salinas, Manisha , Mohabbat, Arya B. , Yang, Juan , Chon, Tony Y. , Bauer, Brent A. , Wahner‐Roedler, Dietlind L. , Wahner-Roedler, Dietlind L , Chen, Weizhi

Mayo Clinic

SAGE Open Medicine | March 30, 2022 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1177/20503121221086712 | PMID 35371484 Get It

Objective: Mental health problems among children and adolescents are increasingly observed during the outbreak of COVID-19, leading to significant healthcare concerns. Survey studies provide unique opportunities for research during this pandemic, while there are no existing systematic reviews in this setting. The objective was to summarize existing survey studies addressing the effects of the current COVID-19 pandemic on the mental health of children and adolescents. Methods: For this systematic review, we performed an electronic search in multiple databases from December 2019 to December 2020. The quality appraisal of the included studies was performed with the Critical Appraisal Skills Programme Qualitative Checklist. Because of the high methodological heterogeneity between studies, a narrative synthesis of the qualitative data was used. Results: In total, 35 survey studies with 65,508 participants, ranging from 4 to 19 years of age, are included in this review. Anxiety (28%), depression (23%), loneliness (5%), stress (5%), fear (5%), tension (3%), anger (3%), fatigue (3%), confusion (3%), and worry (3%) were the most common mental health issues reported. Children and adolescents with psychiatric and/or developmental disorders, such as severe obesity, chronic lung disease, attention deficit hyperactivity disorder, cystic fibrosis, and obsessive-compulsive disorders, were especially vulnerable to the mental health effects of the COVID-19 pandemic. Age, gender, psychological quality, and negative coping strategies were identified as risk factors for the development of mental health problems. Social and family support, along with a positive coping style, was associated with better outcomes. Conclusion: The impact of the COVID-19 pandemic on mental health of children and adolescents is multifaceted and substantial. Survey studies regarding child and adolescent mental health amid COVID-19 indicated that anxiety, depression, loneliness, stress, and tension are the most observed symptoms. Positive coping strategies with family and social support may be important to achieving better outcomes. Due to limited available evidence, more well-designed studies in this area are urgently needed.
How do I implement an outpatient program for the administration of convalescent plasma for COVID‐19?
Bloch, Evan M. , Tobian, Aaron A.R. , Gniadek, Thomas J. , Cachay, Edward R. , Kafka, Kimberly, Marshall, Christi E., Heath, Sonya L. , Forthal, Donald N. , Fukuta, Yuriko , Huamán, Moisés A. , Ziman, Alyssa , Adamski, Jill , Gerber, Jonathan M. , Cruser, Daniel, Patel, Bela , Metcalf, Ryan A. , Reisler, Ronald B. , Yarava, Anusha , Lane, Karen , McBee, Nichol , Gawad, Amy L., Abinante, Matthew, Broderick, Patrick , Sullivan, David , Ziman, Alyssa , Adamksi, Jill , Raval, Jay S , Metcalf, Ryan A , Tobian, Aaron A R , Huaman, Moises A , Sullivan, David J , Shoham, Shmuel , Hanley, Daniel F. , Meisenberg, Barry R. , Shenoy, Aarthi , Paxton, James H , Levine, Adam C , Kassaye, Seble , Mosnaim, Giselle S , Anjan, Shweta , Raval, Jay S. , Zand, Martin S. , Broderick, Patrick B., Casadevall, Arturo , Gebo, Kelly A

Mayo Clinic

Transfusion | March 30, 2022 | Volume: 62 | Issue: 5 | Pages: 933-941

10.1111/trf.16871 | PMID 35352362 Get It

AbstractConvalescent plasma, collected from donors who have recovered from a pathogen of interest, has been used to treat infectious diseases, particularly in times of outbreak, when alternative therapies were unavailable. The COVID‐19 pandemic revived interest in the use of convalescent plasma. Large observational studies and clinical trials that were executed during the pandemic provided insight into how to use convalescent plasma, whereby high levels of antibodies against the pathogen of interest and administration early within the time course of the disease are critical for optimal therapeutic effect. Several studies have shown outpatient administration of COVID‐19 convalescent plasma (CCP) to be both safe and effective, preventing clinical progression in patients when administered within the first week of COVID‐19. The United States Food and Drug Administration expanded its emergency use authorization (EUA) to allow for the administration of CCP in an outpatient setting in December 2021, at least for immunocompromised patients or those on immunosuppressive therapy. Outpatient transfusion of CCP and infusion of monoclonal antibody therapies for a highly transmissible infectious disease introduces nuanced challenges related to infection prevention. Drawing on our experiences with the clinical and research use of CCP, we describe the logistical considerations and workflow spanning procurement of qualified products, infrastructure, staffing, transfusion, and associated management of adverse events. The purpose of this description is to facilitate the efforts of others intent on establishing outpatient transfusion programs for CCP and other antibody‐based therapies.